Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Avelox Gains Coverage for MDR-TB via Public Knowledge Filing
Japan’s Ministry of Health, Labor and Welfare (MHLW) said on March 11 that Bayer Yakuhin’s Avelox (moxifloxacin) has become eligible for public health coverage for the treatment of multidrug-resistant tuberculosis, along with three other medicines. The coverage was granted prior…
To read the full story
Related Article
- Japan Panel Green-Lights GSK’s Hep B Drug, Brinsupri, Hyrnuo
July 28, 2026
- Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
- MHLW Seeks Sponsors for 6 High-Need Unapproved, Off-Label Drugs
July 2, 2026
- MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
- MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
REGULATORY
- Unami Tapped as Japan’s New Top Finance Bureaucrat
August 3, 2026
- MHLW Names Uchiyama New Pharma Bureau Chief in Senior Shakeup
August 3, 2026
- Japan to Ease Olanzapine Diabetes Contraindication for Antiemetic Use
July 31, 2026
- Pipe Damage Causes Water Leak at Sawai Plant after Quake: MHLW
July 30, 2026
- MHLW Urges Stable Supply of Drugs after Kumamoto Earthquake
July 30, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…